BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15125967)

  • 21. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
    Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of (R)- and (S)-isomer of 7-methyl- or 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]- purin-5-one.
    Suzuki H; Nomura M; Miyamoto K; Sawanishi H; Yamamoto K
    Biol Pharm Bull; 2004 Mar; 27(3):357-60. PubMed ID: 14993802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.
    Gewald R; Rueger C; Grunwald C; Egerland U; Hoefgen N
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6652-6. PubMed ID: 21983442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.
    Van der Mey M; Bommelé KM; Boss H; Hatzelmann A; Van Slingerland M; Sterk GJ; Timmerman H
    J Med Chem; 2003 May; 46(10):2008-16. PubMed ID: 12723963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors.
    Martínez A; Castro A; Gil C; Miralpeix M; Segarra V; Doménech T; Beleta J; Palacios JM; Ryder H; Miró X; Bonet C; Casacuberta JM; Azorín F; Piña B; Puigdoménech P
    J Med Chem; 2000 Feb; 43(4):683-9. PubMed ID: 10691694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
    Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example.
    Castro A; Jerez MJ; Gil C; Calderón F; Doménech T; Nueda A; Martínez A
    Eur J Med Chem; 2008 Jul; 43(7):1349-59. PubMed ID: 18082290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
    Castro A; Jerez MJ; Gil C; Martinez A
    Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The purines: potent and versatile small molecule inhibitors and modulators of key biological targets.
    Legraverend M; Grierson DS
    Bioorg Med Chem; 2006 Jun; 14(12):3987-4006. PubMed ID: 16503144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based design, synthesis, and antimicrobial activity of purine derived SAH/MTA nucleosidase inhibitors.
    Tedder ME; Nie Z; Margosiak S; Chu S; Feher VA; Almassy R; Appelt K; Yager KM
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3165-8. PubMed ID: 15149667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular docking study and development of an empirical binding free energy model for phosphodiesterase 4 inhibitors.
    Oliveira FG; Sant'Anna CM; Caffarena ER; Dardenne LE; Barreiro EJ
    Bioorg Med Chem; 2006 Sep; 14(17):6001-11. PubMed ID: 16843671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiotonic agents. 3. A topographical model of the cardiac cAMP phosphodiesterase receptor.
    Erhardt PW; Hagedorn AA; Sabio M
    Mol Pharmacol; 1988 Jan; 33(1):1-13. PubMed ID: 2826995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phytotoxins from Hofmeisteria schaffneri: isolation and synthesis of 2'-(2' '-hydroxy-4' '-methylphenyl)-2'-oxoethyl acetate1.
    Pérez-Vásquez A; Reyes A; Linares E; Bye R; Mata R
    J Nat Prod; 2005 Jun; 68(6):959-62. PubMed ID: 15974630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors.
    Ochiai H; Odagaki Y; Ohtani T; Ishida A; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Kobayashi K; Nakai H; Toda M
    Bioorg Med Chem; 2004 Oct; 12(19):5063-78. PubMed ID: 15351390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors.
    Tait A; Luppi A; Hatzelmann A; Fossa P; Mosti L
    Bioorg Med Chem; 2005 Feb; 13(4):1393-402. PubMed ID: 15670947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Inhibition of cyclic nucleotide phosphodiesterase from rabbit heart by hydroxypyridines].
    Polyansky NB; Smirnov LD; Shvedova AA; Kagan VE; Tkachuk VA
    Vopr Med Khim; 1983; 29(1):123-7. PubMed ID: 6301154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase.
    Chang YT; Choi G; Bae YS; Burdett M; Moon HS; Lee JW; Gray NS; Schultz PG; Meijer L; Chung SK; Choi KY; Suh PG; Ryu SH
    Chembiochem; 2002 Sep; 3(9):897-901. PubMed ID: 12210991
    [No Abstract]   [Full Text] [Related]  

  • 39. Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors.
    El-Sharkawy LY; El-Sakhawy RA; Abdel-Halim M; Lee K; Piazza GA; Ducho C; Hartmann RW; Abadi AH
    Arch Pharm (Weinheim); 2018 May; 351(5):e1800018. PubMed ID: 29656464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
    Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
    Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.